Silymarin, the active extract from milk thistle, has been extensively used in patients with liver disease of different etiology. Although silymarin is a complex of 7 flavonolignans and polyphenols, silibinin is usually regarded as the most active component. In vitro and in vivo studies indicate that silymarin and silibinin protect the liver from oxidative stress and sustained inflammatory processes, mainly driven by Reactive Oxygen Species (ROS) and secondary cytokines. Oxidative stress and inflammation are also involved in cellular damage of many other tissues and their role in the development and toxic reactions in patients receiving cancer therapies is established. The protective effects of silymarin and silibinin, demonstrated in various tissues, suggest a clinical application in cancer patients as an adjunct to established therapies, to prevent or reduce their toxicity. Here we discuss the possible mechanism of the protective action of silymarin and silibinin, focusing on cancer therapies as agents causing cellular damage.
Saller R., Meier R., Brignoli R.The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035-2063.
2.
Rambaldi A., Jacobs BP, Iaquinto G., Gluud C.Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic Cochrane Hepato-Biliary Group review with meta-analyses of randomized clinical trials. Am J Gastroenterol.2005;100: 2583-2591.
3.
Rainone F.Milk thistle. Am Fam Physician. 2005;72:1285-1288.
4.
Weneke U., Earl J., Seydel C., et al. Potential health risk of complementary alternative medicines in cancer patients. Br J Cancer.2004;90:408-413.
5.
Sparreboom A. , Cox MC, Acharya MR, Figg WDHerbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol.2004;22:2489-2503.
6.
Molassiotis A., Fernadez-Ortega P., Pud D., et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol.2005;16:655-663.
7.
Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther.2004;76:428-440.
8.
Davis-Searles PR, Nakanishi Y., Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res.2005;65:4448-4457.
9.
Singh RP, Agarwal R.Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Current DrugTargets. 2006;7:345-354.
10.
Dvorak Z., Kosina P., Walterova D., Simanek V., Bachieda P., Ulrichova J.Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum . Toxicol Lett.2003;137:201-212.
11.
Moon YJ, Wang X., Morris MEDietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro.2006;20:187-210.
12.
Aggarwal BB , Shishodia S.Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol.2006; 71:1397-1421.
13.
Tyagi AK, Agarwal C., Chan DC, Agarwal R.Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004; 11:493-499.
14.
Psotova J., Chlopcikova S., Grambal F., et al. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res. 2002;16:S63-S67.
15.
Scambia G., De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer. 1996;32A:877-882.
16.
Manna SK, Mukohopadhyay A., Van NT, Aggarwal BBSilymarin suppresses TNF induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. J Immunol.1999;161:6800-6809.
17.
Valko M., Rhodes CI, Moncol J., Izakovic M., Mazur M.Free radicals, metals and antioxidants in oxidative stress-induced cancer . Chem Biol Interact.2006;160:1-40.
18.
Pervaiz S.Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets. Curr Pharm Des. 2006;12:4469-4477.
19.
Soto C., Mena R., Luna J., et al. Silymarin induces recovery of pancreatic function after alloxan damage to rats. Life Sci.2004;75:2167-2180.
20.
Dehmlow C., Murawski N., De Groot H.Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci.1996 ;58:1591-1600.
21.
Muezes G., Deak G., Lang I., Nekam K., Niederland V., Feher J.Effects of silymarin treatment on the antioxidant defence system and lipid peroxidation in patients with chronic alcoholic liver disease (a double blind study). Orvosi Hetilap. 1990;131: 863-867.
22.
Floyd J., Mirza I., Sachs B., Perry MCHepatotoxicity of chemotherapy. Semin Oncol.2006;33:50-67.
23.
Logan RM, Gibson RJ, Sonis ST, Keefe DMNuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol.2007;43:395-401.
24.
Yeoh AS, Bowen JM, Gibson RJ, Keefe DMNuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys.2005 ;63:1295-1303.
25.
Navarro VJ, Senior JRDrug-related hepatotoxicity. N Engl J Med.2006;354:731-739.
26.
Gazak R., Svobodova A., Psotova J., et al. Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem. 2004;12:5677-5687.
27.
Ladas EJ, Kelly KMMilk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Altern ComplemMed.2003;9:411-416.
28.
Ladas EJ, Cheng B., Hughes D., et al. Milk thistle (Silybum marianum) is associated with reductions in liver function tests (LFTs). Abstract presented at: Society for Integrative Oncology 3rd International Conference; November 9-11, 2006; Boston, Mass.
29.
Invernizzi R., Remuzzi S., Ciani D., Ascari E.Silymarine during maintenance therapy of acute promyelocytic leukaemia. Haematologica. 1993 ;78:340-341.
30.
Singh RP, Agarwal R.Mechanisms and preclinical efficacy of silibinin in preventing skin cancer . Eur J Cancer.2005;41: 1969-1979.
31.
Singh RP, Agarwal R.Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog.2006;45:436-442.
32.
Dobrovolskaia MA, Kozlov SVInflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer DrugTargets. 2005;5:325-344.
33.
Kang JS, Jeon YJ, Kim HM, Han SH, Yang KHInhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther.2002; 302:138-144.
34.
Qi L., Singh RP, Lu Y., et al. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther.2003;2:526-531.
35.
Hannay Jaf, Yu D.Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther.2003;2:532-533.
36.
Yoo HG, Jung SN, Hwang YSInvolvement of NF-κB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Molec Med.2004;13:81-86.
37.
Zhong X., Zhu Y., Lu Q., et al. Silymarin causes caspase activation and apoptosis in K562 leukemia cells through inactivation of Akt pathways. Toxicology. 2006;227:211-216.
38.
Singh RP, Tyagy AK, Zhao J., et al. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinase and induction of apoptosis. Carcinogenesis. 2002;23:499-510.
39.
Singh RP, Dhanalakshmi S., Tyagi AK, et al. Dietary feeding of silibinin inhibits advanced human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein 3 levels. Cancer Res.2002;62: 3063-3069.
40.
Hoh C., Boocock D., Marczylo T., et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res.2006; 12:2944-2950.
41.
Gazak R., Walterova D., Kren V.Silybin and silymarin—new and emerging applications in medicine. Curr Med Chem.2007; 14:315-338.
42.
Lewerenz V. , Hanelt S., Nastevska C., et al. Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity. Toxicology. 2003;191:179-187.
43.
Mansour HH, Hafez HF, Fahmy NMSilymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J Biochem Mol Biol.2006;39:656-661.
44.
Neuman MG, Cameron RG, Haber JA, et al. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem.1999;32:519-536.
45.
Pradeep K., Mohan CV, Gobianand K., Karthikeyan S.Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol.2007;560:110-116.
46.
Ramadan LA, Roushdy HM, Abu Senna GM, et al. Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res. 2002;45:447-454.
47.
Song Z., Deaciuc I., Song M., et al. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol Clin Exp Res. 2006;30:407-413.
48.
Schumann J. , Prockl J., Kiemer AK, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol.2003;39: 333-340.
49.
Chang JW, Kim CS, Kim SB, Park SK, Park JS, Lee K.Proinflammatory cytokine-induced NF-kappaB activation in human mesangial cells is mediated through intracellular calcium but not ROS: effects of silymarin. NephronExp Nephrol.2006;103:156-165.
50.
Alidoost F. , Gharagozloo M., Bagherpour B., et al. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol. 2006;6:1305-1310.
51.
Wang YK, Hong YJ, Fluang ZQProtective effects of silybin on human umbilical vein endothelial cell injury induced by H202 in vitro. Vascul Pharmacol.2005;43:198-206.
52.
Wang MJ, Lin WW, Chen HL, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci.2002;16:2103-2112.
53.
Svobodova A. , Walterova D., Psotova J.Influence of silymarin and its flavonolignans on H2O2-induced oxidative stress in human keratinocytes and mouse fibroblasts. Burns.2006;32: 973-979.
54.
Lahiri-Chatterjee M., Katiyar SK, Mohan RR, Agarwal R.A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumour promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res.1999 ;59:622-632.
55.
Mallikarjuna G., Dhanalakshmi S., Singh RP, Agarwal C., Agarwal R.Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res.2004;64: 6349-6356.
56.
Singh RP, Dhanalakshmi S., Tyagi AK, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res.2002;62:3063-3069.
57.
Singh RP, Mallikarjuna GU, Sharma G., et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappa-B-mediated inducible chemoresistance. Clin Cancer Res.2004;10:8641-8647.
58.
Singh RP, Deep G., Chittezhath M., et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst.2006 ;98:846-855.
59.
Kohno H., Tanaka T., Kawabata K., et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer. 2002;101:461-468.
60.
Volate SR, Davenport DM, Muga SJ, Wargovich MJModulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis . 2005;26:1450-1456.
61.
Barzaghi N. , Crema F., Gatti G., Pifferi G., Perucca E.Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet.1990;15:333-338.
